Clinical trials
Renal Cell Carcinoma clinical trials
Below are recruiting renal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 526 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05157763RecruitingPhase 1/Phase 2
Test ointment for small basal cell skin cancers
This Phase 1/2 trial tests EscharEx (an investigational treatment) to see if it is safe and works on a single small basal cell skin cancer on the trunk or upper arms. You might qualify if your cancer fits specific size and location rules and you have not had radiation to that spot.
Aventura, FloridaAges 18 years+ - NCT05214885Recruiting
Study biomarkers in kidney cancer and healthy people
This study looks at blood or body measures called “biomarkers” to understand how lack of oxygen and body energy changes in clear cell kidney cancer. It compares people with kidney cancer to carefully matched healthy volunteers to see what patterns might help improve understanding or future care.
JinanAges Any age - NCT05037825Recruiting
Study gut microbes with immune therapy in several solid cancers
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
Elizabethtown, KentuckyAges 18 years+ - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT05753839Recruiting
Testing surgery plus immunotherapy for metastatic kidney cancer
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
SeoulAges 18 years+ - NCT06194669Recruiting
VHL disease and kidney tumor risk study
This study looks at how early changes in kidney cells can lead to tumors in people with VHL disease. It may help understand why some people develop kidney cancer and how to prevent it.
MilanAges 18 years+ - NCT06211790RecruitingPhase 2
Targeted first-line treatment for advanced kidney cancer based on protein profile
This trial tests a first-line precision treatment for clear cell kidney cancer that has spread or cannot be removed. It aims to match the treatment to your cancer's protein profile to improve outcomes.
ShanghaiAges 18–75 - NCT03414827Recruiting
Genetic testing study for kidney cancer
This study looks at genetic features of kidney cancer by testing tumor samples. The goal is to find biomarkers—specific signs—that may help predict what kind of kidney cancer it is.
RoskildeAges Any age - NCT05098119RecruitingPhase 2
Study drugs before surgery for mouth or throat cancer
This Phase 2 trial tests giving the immunotherapy drug sintilimab before surgery, along with fewer chemotherapy cycles. The goal is to shrink or control oral or throat squamous cell cancers while keeping side effects lower, before the tumor is removed.
Guangzhou, GuangdongAges 18–80 - NCT06336187Recruiting
Active monitoring for small kidney tumors
This study tests whether closely monitoring small kidney tumors (less than 4 cm) with regular imaging is a safe and effective option for people who cannot or choose not to have immediate treatment. It involves a biopsy at the start to confirm the tumor type.
NovaraAges 18 years+ - NCT06399419RecruitingPhase 1
Study of CBM588 with immunotherapy for advanced kidney cancer
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
Duarte, CaliforniaAges 18 years+ - NCT07833085Recruiting
Imaging test for solid tumors using a special tracer
This study tests a new imaging method that uses a special tracer to find solid tumors in the body. It may help doctors see tumors more clearly and guide treatment.
Wuhan, HubeiAges 18 years+ - NCT06321250RecruitingPhase 1
Study of a new tablet for advanced kidney cancer
This study tests a new tablet (JMKX003948) for people with advanced clear cell kidney cancer. It aims to see if the drug is safe and how well it works.
BeijingAges 18 years+ - NCT07805122Recruiting
Monitoring cabozantinib levels to manage side effects in kidney cancer
This study looks at whether closer monitoring of cabozantinib levels in the blood can help doctors manage side effects better. It's for people with advanced kidney cancer who are already planning to take cabozantinib.
Aviano, PordenoneAges 18 years+ - NCT06553339RecruitingPhase 1
A study of HS-10516 for VHL syndrome tumors
This trial tests a new drug called HS-10516 in people with VHL syndrome or advanced kidney cancer. The goal is to see if the drug can shrink tumors and what side effects it might have.
Beijing, Beijing MunicipalityAges 18–80 - NCT07770802RecruitingPhase 1
Study of an investigational cell therapy for advanced kidney cancer
This trial tests an investigational medicine called HS-IT101 for people with advanced kidney cancer that hasn't responded to standard treatments. The goal is to see if this new therapy can help shrink or control the cancer.
BeijingAges 18–75 - NCT07744932RecruitingPhase 2
Radiation plus drug combo for kidney cancer that has spread a little
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
Shijiazhuang, HebeiAges 18 years+ - NCT07748988RecruitingPhase 1
Casdatifan for advanced kidney cancer that has stopped responding
This study tests a new pill called casdatifan for people with advanced kidney cancer that has not improved after standard treatments. The goal is to see if the drug can shrink tumors and be safe to take.
Nashville, TennesseeAges 18–100 - NCT06613269RecruitingPhase 2
PET-guided radiation therapy for clear cell kidney cancer
This trial tests whether a special PET/CT scan (68Ga-NY104) can help guide radiation therapy for people with clear cell kidney cancer. The goal is to make radiation more precise and effective for treating tumors that haven't spread too much.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07688187RecruitingPhase 1
Theranostic pair for advanced kidney cancer
This trial tests a radioactive drug and its imaging partner to find and treat kidney cancer that has spread. You get a scan first to see if the cancer absorbs the drug, and if it does, you receive the therapy.
Omaha, NebraskaAges 18 years+ - NCT07671417RecruitingEarly Phase 1
Imaging study for advanced clear cell kidney cancer
This early-phase study uses a special imaging agent called RYZ512 to see how it works in people with advanced clear cell kidney cancer that has spread. Participants will receive RYZ512 and have scans; you may qualify if you can pause certain medications temporarily.
Saint Leonards, New South WalesAges 18 years+ - NCT07667335RecruitingPhase 1/Phase 2
Combination therapy for advanced bladder cancer
This trial tests a combination of three drugs for advanced bladder cancer (including cancer of the renal pelvis or ureter) that has not been treated before. The goal is to see if the combination is safe and effective.
Seattle, WashingtonAges 18 years+ - NCT06519760Recruiting
68Ga-C1 PET/CT imaging for clear cell kidney cancer
This trial uses a special imaging scan (68Ga-C1 PET/CT) to see kidney cancer more clearly. It helps doctors find and understand clear cell renal cell carcinoma, a common type of kidney cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07657325Recruiting
Toripalimab for high-risk kidney cancer that has been removed
This trial tests whether the drug toripalimab can prevent kidney cancer from coming back in people who have had their kidney and any visible metastases surgically removed. It focuses on patients with high-risk features or who had some metastatic spots taken out completely.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Renal Cell Carcinoma trials by city
Studies with a site in or near these metro areas.
Renal Cell Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for renal cell carcinoma?
- Yes. Clin2 currently lists 526 recruiting renal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.